NCT06033586View on ClinicalTrials.gov

Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2027

Conditions
Polycythemia Vera
Interventions
DRUG

Open-label rusfertide

subcutaneous rusfertide

Trial Locations (1)

70433

Pontchartrain Cancer Care, Covington

All Listed Sponsors
lead

Protagonist Therapeutics, Inc.

INDUSTRY

NCT06033586 - Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera | Biotech Hunter | Biotech Hunter